TY - JOUR
AB - Inpharma 1328 - 9 Mar 2002 PPI test strategy warranted in Table. Costs and outcomes of managing patients patients with GORD symptoms with GORD symptoms Parameter Traditional PPI* test A proton pump inhibitor (PPI) test strategy affords strategy strategy primary-care physicians an ‘accessible, cost-effective Cost per 1045 1172 and practical approach’ for managing patients with patient symptoms suggestive of gastro-oesophageal reflux ($US)** disease (GORD), says a US-based investigative team. Patients 50 75 The investigators constructed a decision-analysis symptom- free at 1 model using clinical data from published literature to year (%) compare the cost effectiveness of the following two Cost per 2089 1565 treatment strategies for a hypothetical cohort of patients symptom- ** with GORD symptoms. free Traditional strategy: patients received standard-dose patient H -receptor antagonists for 6 weeks followed by ($US) 6-week sequential trials of high-dose H -receptor Incremental . 510 cost per antagonists and standard-dose PPIs for those with symptom- persistent symptoms (step-up approach). free Responders were stepped down to less intensive patient medical therapy. ($US) PPI test strategy: patients received a 7-day trial of * proton pump inhibitor high-dose PPI followed by standard-dose ** Costs (1997 values) were those related to drug acquisition, physician H -receptor 
TI - PPI test strategy warranted in patients with GORD symptoms
JF - Inpharma Weekly
DO - 10.2165/00128413-200213280-00016
DA - 2013-02-09
UR - https://www.deepdyve.com/lp/springer-journals/ppi-test-strategy-warranted-in-patients-with-gord-symptoms-4xgpYL8qa8
SP - 8
EP - 8
VL - 1328
IS - 1
DP - DeepDyve
ER -